Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma.

de Mel S, Chen Y, Lin A, Soh TG, Ooi M, Yap ES, Donato LKS, Halim NAA, Mah J, Lim K, Poon LM, Tan B, Yelly, Lim HL, Koh LP, Tai BC, Chen Z, Chng WJ, Gopalakrishnan SK, Tan LK.

Hematol Oncol Stem Cell Ther. 2018 Dec;11(4):225-232. doi: 10.1016/j.hemonc.2018.04.001. Epub 2018 Apr 23.

2.

Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma.

Annunziata M, Celentano M, Pocali B, D'Amico MR, Palmieri S, Viola A, Copia C, Falco C, Del Vecchio L, Ferrara F.

Ann Hematol. 2006 Jun;85(6):394-9. Epub 2006 Mar 15.

PMID:
16538502
3.

Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.

Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1128-35. doi: 10.1016/j.bbmt.2012.01.005. Epub 2012 Jan 14.

4.

Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study.

Samaras P, Rütti MF, Seifert B, Bachmann H, Schanz U, Eisenring M, Renner C, Susanne Müller AM, Schmidt A, Mischo A, Fuchs I, Bargetzi M, Manz MG, Stupp R, Petrausch U, Stenner-Liewen F.

Biol Blood Marrow Transplant. 2018 Apr;24(4):694-699. doi: 10.1016/j.bbmt.2017.12.775. Epub 2017 Dec 12.

5.

Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.

Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M.

J Clin Apher. 2013 Oct;28(5):359-67. doi: 10.1002/jca.21280. Epub 2013 Jun 14.

PMID:
23765597
6.

Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma.

Gettys SC, Gulbis A, Wilhelm K, Sasaki K, Dinh Y, Rondon G, Qazilbash MH.

Eur J Haematol. 2017 Apr;98(4):388-392. doi: 10.1111/ejh.12843. Epub 2017 Jan 30.

PMID:
28009447
7.

A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.

Kuan JW, Su AT, Wong SP, Sim XY, Toh SG, Ong TC, Rajasuriarr JS, Lim SH, Guan YK, Liew HK, Liew PK, Tan JT, Kori AN, Cheng YY, Tan SM, Chang KM.

Transfus Apher Sci. 2015 Oct;53(2):196-204. doi: 10.1016/j.transci.2015.03.017. Epub 2015 Mar 30.

PMID:
25910537
8.
9.

Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Tuchman SA, Bacon WA, Huang LW, Long G, Rizzieri D, Horwitz M, Chute JP, Sullivan K, Morris Engemann A, Yopp A, Li Z, Corbet K, Chao N, Gasparetto C.

J Clin Apher. 2015 Jun;30(3):176-82. doi: 10.1002/jca.21360. Epub 2014 Oct 8.

10.

Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.

Winkelmann N, Desole M, Hilgendorf I, Ernst T, Sayer HG, Kunert C, Mügge LO, Hochhaus A, Scholl S.

J Cancer Res Clin Oncol. 2016 Dec;142(12):2603-2610. Epub 2016 Sep 17.

PMID:
27640002
11.

Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.

Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A, Craig M, Hamadani M.

Bone Marrow Transplant. 2013 Oct;48(10):1279-84. doi: 10.1038/bmt.2013.52. Epub 2013 Apr 15.

PMID:
23584435
12.

Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.

Benyamini N, Avivi I, Dann EJ, Zuckerman T, Lavi N, Katz T.

Ann Hematol. 2017 Mar;96(3):461-467. doi: 10.1007/s00277-016-2897-2. Epub 2016 Dec 24.

PMID:
28013359
13.

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.

Baertsch MA, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, Noppeney R, Martin H, Lindemann HW, Haenel M, Nogai A, Scheid C, Salwender H, Fenk R, Graeven U, Reimer P, Schmidt-Hieber M, Goerner M, Schmidt-Wolf IGH, Klein S, Ho AD, Goldschmidt H, Wuchter P.

Eur J Haematol. 2017 Jul;99(1):42-50. doi: 10.1111/ejh.12888. Epub 2017 May 24.

PMID:
28370401
14.

Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.

Maul JT, Stenner-Liewen F, Seifert B, Pfrommer S, Petrausch U, Kiessling MK, Schanz U, Nair G, Mischo A, Taverna C, Schmidt A, Bargetzi M, Stupp R, Renner C, Samaras P.

J Clin Apher. 2017 Feb;32(1):21-26. doi: 10.1002/jca.21459. Epub 2016 Mar 22.

PMID:
27001243
15.

Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.

Shimura Y, Kuroda J, Uchiyama H, Kawata-Iida E, Tsutsumi Y, Nagoshi H, Mizutani S, Yamamoto-Sugitani M, Matsumoto Y, Kobayashi T, Horiike S, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M.

J Clin Apher. 2013 Oct;28(5):368-73. doi: 10.1002/jca.21283. Epub 2013 Jun 27.

PMID:
23804501
16.

Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.

Lin TL, Wang PN, Kuo MC, Hung YH, Chang H, Tang TC.

J Clin Apher. 2016 Oct;31(5):423-8. doi: 10.1002/jca.21421. Epub 2015 Sep 5.

PMID:
26340986
17.
18.

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma.

Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamäki E, Remes K.

Bone Marrow Transplant. 2003 Mar;31(5):347-51.

PMID:
12634725
19.

[Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].

Pokrovskaia OS, Mendeleeva LP, Urnova ES, Gaponova TV, Gribanova EO, Alekseeva IV, Drokov MIu, Kalinin NN, Gretsov EM, Kliasova GA, Savchenko VG.

Ter Arkh. 2011;83(7):50-7. Russian.

PMID:
21894752
20.

Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.

Samaras P, Pfrommer S, Seifert B, Petrausch U, Mischo A, Schmidt A, Schanz U, Nair G, Bargetzi M, Taverna C, Stupp R, Stenner-Liewen F, Renner C.

Biol Blood Marrow Transplant. 2015 Jan;21(1):74-80. doi: 10.1016/j.bbmt.2014.09.020. Epub 2014 Sep 30.

Supplemental Content

Support Center